Scientists at biomedical firm Gel-Del Technologies have completed trials of a new non-surgical cosmetic treatment designed to improve the appearance of wrinkles.
CosmetaLife is an injectable dermal filler that could provide a more effective alternative to existing therapies.
The product produced better results than Restylane - the first dermal filler to market over 12 years ago - for the first three months after treatment, and was as effective at 12 months after treatment.
Dr David Masters, founder and president of Gel-Del Technologies, commented: "It is exciting to see the first human use of this technology over the past 19 months.
"Based on the results of our 12-month clinical study, CosmetaLife provides a better early performance than hyaluronic acid products, and a lasting effect expected to persist longer due to an actual dermal correction."
Dr Masters concluded that the company are "pleased" with the clinical trials and "eager" to gain approval for the filler.